Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merus N.V. - Common Shares
(NQ:
MRUS
)
52.66
+0.06 (+0.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merus N.V. - Common Shares
< Previous
1
2
3
4
5
6
Next >
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
June 04, 2025
Via
Benzinga
Merus N.V. Announces Pricing of Public Offering of Common Shares
June 04, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
June 03, 2025
From
Merus N.V.
Via
GlobeNewswire
What's Going On With Merus Stock Monday?
January 13, 2025
Merus announced a research collaboration and license agreement with Biohaven.
Via
Benzinga
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio?
June 01, 2025
11 mid-cap stocks soared last week, including LZ Technology, Centrus Energy, e.l.f Beauty, Merus, Oklo, NuScale Power, Informatica, BRP, Box, Joby Aviation, and C3.ai.
Via
Benzinga
Merus to Present at Upcoming Investor Conferences
May 27, 2025
From
Merus N.V.
Via
GlobeNewswire
D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
May 25, 2025
Top mid-cap stocks gained up to 53.47% in the last week, including QBTS, RGC, AAP, MRUS, OKLO, SBSW, and BGM. Are they in your portfolio?
Via
Benzinga
Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?
May 23, 2025
Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab...
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
May 23, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
May 23, 2025
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.
Via
Stocktwits
Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday
May 23, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
May 23, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via
Investor's Business Daily
Discover the top movers in Friday's pre-market session.
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
May 22, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
May 15, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at BofA Securities 2025 Health Care Conference
May 08, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
May 07, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
April 23, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
February 27, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at Upcoming Investor Conferences
February 25, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Shares Are Up Today: What's Going On?
February 18, 2025
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for...
Via
Benzinga
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
February 18, 2025
This marks the second BTD for petosemtamab in HNSCC
From
Merus N.V.
Via
GlobeNewswire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
February 13, 2025
Via
Benzinga
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
February 13, 2025
From
Merus N.V.
Via
GlobeNewswire
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
February 05, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
January 12, 2025
From
Merus N.V.
Via
GlobeNewswire
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
January 10, 2025
Via
Benzinga
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
December 16, 2024
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.